Telesis Bio EBIT

Telesis Bio (TBIO) currently reports a EBIT of $-28M as of September 2024. That compares with $-38M in the prior-year period — up 25.0% year over year. That is below the Healthcare sector average of $22B. Use the charts on this page to explore Telesis Bio's EBIT history and peer comparisons.

Telesis Bio's EBIT increased from $-38M to $-28M — a 25.0% year-over-year increase (period ending September 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Telesis Bio's EBIT of $-28M is lower than the Healthcare sector average of $22B. That is roughly 100.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Telesis Bio reported $-28M in EBIT as of September 2024. That compares with $-38M in the prior-year period — up 25.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-28M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $22B. From there, open related valuation or income-statement pages for Telesis Bio, and consider following TBIO for alerts when major investors trade the stock.